CO4960663A1 - Fumarato de 2-(-3-(4-(2-t-butil-6-trifluorometilpirimidin- 4-il)piperazin-1-il) propilmecapto)pirimidin-4-ol - Google Patents

Fumarato de 2-(-3-(4-(2-t-butil-6-trifluorometilpirimidin- 4-il)piperazin-1-il) propilmecapto)pirimidin-4-ol

Info

Publication number
CO4960663A1
CO4960663A1 CO98046527A CO98046527A CO4960663A1 CO 4960663 A1 CO4960663 A1 CO 4960663A1 CO 98046527 A CO98046527 A CO 98046527A CO 98046527 A CO98046527 A CO 98046527A CO 4960663 A1 CO4960663 A1 CO 4960663A1
Authority
CO
Colombia
Prior art keywords
piperazin
acid salt
fumaric acid
trifluorometilpirimidin
pumimidate
Prior art date
Application number
CO98046527A
Other languages
English (en)
Inventor
Stefan Blech
Starck Dorothea
Hans-Jorg Treiber
Stefan Koser
Bernd Schafer
Marco Thyes
Thomas Hoger
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of CO4960663A1 publication Critical patent/CO4960663A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56One oxygen atom and one sulfur atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Sal de ácido fumárico de 2-{3-[4-(2-t-butil-6-trifluorome-tilpirimidin-4-il)piperazin-1-il]propilmercapto} pirimidin-4-ol de la fórmula y las formas tautómeras, solvatos e hidratos de la misma. Medicamento que contiene la sal de ácido fumárico o una forma tautómera, un solvato o un hidrato de la misma de acuerdo con la cláusula 1, CARACTERIZADO porque puede administrarse, en caso necesario, junto con portadores y/o sustancias auxiliares fisiológicamente aceptables. Sal de ácido fumárico o una forma tautómera, un solvato o hidrato de la misma de acuerdo con la claúsula 1 utilizada para preparar un medicamento para el tratamiento de enfermedades que responden a la acción de ligandos de dopamina D3 .
CO98046527A 1997-08-14 1998-08-13 Fumarato de 2-(-3-(4-(2-t-butil-6-trifluorometilpirimidin- 4-il)piperazin-1-il) propilmecapto)pirimidin-4-ol CO4960663A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19735410A DE19735410A1 (de) 1997-08-14 1997-08-14 2-{3-[4-(2-t-Butyl-6-trifluormethylpyrimidin-4-yl)piperazin-1-yl]propylmercapto}pyrimidin-4-ol-fumarat

Publications (1)

Publication Number Publication Date
CO4960663A1 true CO4960663A1 (es) 2000-09-25

Family

ID=7839072

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98046527A CO4960663A1 (es) 1997-08-14 1998-08-13 Fumarato de 2-(-3-(4-(2-t-butil-6-trifluorometilpirimidin- 4-il)piperazin-1-il) propilmecapto)pirimidin-4-ol

Country Status (25)

Country Link
US (1) US20010020022A1 (es)
EP (2) EP2272833A1 (es)
JP (1) JP4444492B2 (es)
KR (1) KR100571945B1 (es)
CN (1) CN1267286A (es)
AR (1) AR016605A1 (es)
AT (1) ATE525362T1 (es)
AU (1) AU749575B2 (es)
BG (1) BG104122A (es)
BR (1) BR9811177A (es)
CA (1) CA2301297A1 (es)
CO (1) CO4960663A1 (es)
DE (1) DE19735410A1 (es)
ES (1) ES2374156T3 (es)
HU (1) HUP0003710A3 (es)
ID (1) ID24639A (es)
IL (1) IL134246A (es)
NO (1) NO314935B1 (es)
NZ (1) NZ502675A (es)
PL (1) PL201927B1 (es)
SK (1) SK1182000A3 (es)
TR (1) TR200000406T2 (es)
TW (1) TW467912B (es)
WO (1) WO1999009015A1 (es)
ZA (1) ZA987239B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE402704T1 (de) * 2000-03-27 2008-08-15 Abbott Gmbh & Co Kg Dopamin-d3-rezeptor-liganden zur behandlung von sucht
DE102004027358A1 (de) 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyrimidinverbindungen und ihre Verwendung
EP1778684B1 (en) * 2004-08-09 2009-12-16 Abbott GmbH & Co. KG 4-PIPERAZINYL-PYRIMIDINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D<sb>3</sb> RECEPTOR
CN102887860B (zh) * 2012-09-29 2015-07-01 上海泰坦科技有限公司 4-氯-6-三氟甲基嘧啶类化合物的制备方法
JP6448541B2 (ja) 2012-10-11 2019-01-09 サザン リサーチ インスティテュート アミノアルキルピペラジンの尿素及びアミド誘導体並びにその使用
US9376396B2 (en) 2012-10-22 2016-06-28 AbbVie Deutschland GmbH & Co. KG Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4425143A1 (de) * 1994-07-15 1996-01-18 Basf Ag Substituierte Pyrimidinverbindungen und deren Verwendung

Also Published As

Publication number Publication date
JP2001515070A (ja) 2001-09-18
IL134246A0 (en) 2001-04-30
ID24639A (id) 2000-07-27
NZ502675A (en) 2001-06-29
NO20000665D0 (no) 2000-02-10
IL134246A (en) 2002-11-10
ATE525362T1 (de) 2011-10-15
DE19735410A1 (de) 1999-02-18
KR20010022833A (ko) 2001-03-26
HUP0003710A2 (hu) 2001-10-28
TW467912B (en) 2001-12-11
HUP0003710A3 (en) 2002-01-28
PL201927B1 (pl) 2009-05-29
CN1267286A (zh) 2000-09-20
NO20000665L (no) 2000-02-10
TR200000406T2 (tr) 2000-05-22
AR016605A1 (es) 2001-07-25
JP4444492B2 (ja) 2010-03-31
PL338603A1 (en) 2000-11-06
SK1182000A3 (en) 2000-09-12
KR100571945B1 (ko) 2006-04-18
WO1999009015A1 (de) 1999-02-25
EP2272833A1 (de) 2011-01-12
BR9811177A (pt) 2000-07-25
AU749575B2 (en) 2002-06-27
BG104122A (en) 2000-11-30
US20010020022A1 (en) 2001-09-06
CA2301297A1 (en) 1999-02-25
EP1003728A1 (de) 2000-05-31
ES2374156T3 (es) 2012-02-14
NO314935B1 (no) 2003-06-16
ZA987239B (en) 2000-02-14
AU9342698A (en) 1999-03-08
EP1003728B1 (de) 2011-09-21

Similar Documents

Publication Publication Date Title
AR016351A1 (es) FORMA CRISTALINA BETA DE LA SAL DE ADICIoN DE ÁCIDO METANSULFoNICO DE 4-(4-METILPIPERAZIN-1-ILMETIL)-N-[4-METIL-3-(4-PIRIDIN-3-IL) PIRIMIDIN-2-ILAMINO) FENIL] BENZAMIDA, COMPOSICIoN FARMACÉUTICA, USO DE LA FORMA CRISTALINA PARA LA PREPARACIoN DE UN AGENTE FARMACOLoGICO, Y PROCESOS PARA LA PREPARACIo
DE69109284D1 (de) Verwendung von fluorierten löslichen tensiden zur herstellung von aerosolarzneimitteln mit dosierter abgabe.
ECSP055746A (es) Antagonistas de cgrp elegidos, procedimiento para su preparación, así como su empleo como medicamentos
ES2155473T3 (es) Composicion veterinaria que contiene un inhibidor de las bombas de protones.
HU9400727D0 (en) 1-[(4-chloro-phenyl)-phenyl-methyl]-4-[(4-methyl-phenyl)-sulfonyl]-piperazine enanthiomeres and process for producing them
DK0799209T3 (da) Sulfonamider
AU6473601A (en) Gabapentin analogues for sleep disorders
AU1826202A (en) Treatment of gastrointestinal stromal tumors
BR0012901A (pt) Medicamentos de ß - carbolina
BR0312873A (pt) 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil] benzamida para tratamento de doenças associadas com ret cinase mutante
CO4960663A1 (es) Fumarato de 2-(-3-(4-(2-t-butil-6-trifluorometilpirimidin- 4-il)piperazin-1-il) propilmecapto)pirimidin-4-ol
ES2191942T3 (es) Nueva utilizacion de un antagonista especifico de los receptores 5ht2a.
ATE252383T1 (de) Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
AR034142A1 (es) Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion
ATE260655T1 (de) Verwendung von stickstoffhaltigen aromatischen heterozyklusderivaten zur topischen behandlung von epithelerkrankungen
ES2191908T3 (es) 4-aminopirrol(3,2-d)pirimidinas como antagonistas del receptor del neuropeptido.
DE69941897D1 (de) Arzneimittel für nicht-cardiogene diastolische dysfunktion
AR023452A1 (es) Utilizacion del osanetant para preparacion de medicamentos utiles en el tratamiento de los trastornos del humor
ATE294572T1 (de) Verwendung von gepirone metabolite zur erstellungs eines medicaments zur behandlung von neurologischer krankheiten
NO941084L (no) Neuroleptiske 2-substituerte perhydro-1-H-pyrido[1,2-aÅpyraziner
GB9126874D0 (en) Medicaments
BR9910185A (pt) Uso de um composto, e, processo para o tratamento de um paciente que sofre de, ou em risco de, uma doença micobacteriana
ATE247462T1 (de) Verwendung von metformin gegen die gewichtszunahme, die mit valproat und andere psychotropische arzneimittel verbunden ist
NO975790D0 (no) Anvendelse av allylaminderivater slik som terbinafin, i fremstillingen av et medikament for behandling av helikobacterpylori-infeksjonsassosierte sykdommer
AR026242A1 (es) Empleo de 2-amino-3,4-dihidro-quinazolinas para la preparacion de un medicamento para el tratamiento o profilaxis de enfermedades provocadas por estadosisquemicos